Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.verified

AGLE

Price:

$12.01

Market Cap:

$1.37B

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly kno...[Read more]

Industry

Biotechnology

IPO Date

2016-04-07

Stock Exchange

NASDAQ

Ticker

AGLE

The PE Ratio as of December 2024 (TTM) for Aeglea BioTherapeutics, Inc. (AGLE) is -0.16

According to Aeglea BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.16. This represents a change of -96.88% compared to the average of -5.19 of the last 4 quarters.

Aeglea BioTherapeutics, Inc. (AGLE) Historical PE Ratio (quarterly & annually)

How has AGLE PE Ratio performed in the past?

The mean historical PE Ratio of Aeglea BioTherapeutics, Inc. over the last ten years is -4.52. The current -0.16 PE Ratio has changed 258.05% with respect to the historical average. Over the past ten years (40 quarters), AGLE's PE Ratio was at its highest in in the December 2014 quarter at 0. The PE Ratio was at its lowest in in the June 2021 quarter at -16.72.

Quarterly (TTM)
Annual

Average

-4.52

Median

-3.32

Minimum

-12.92

Maximum

-0.44

Aeglea BioTherapeutics, Inc. (AGLE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Aeglea BioTherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 66.46%

Maximum Annual PE Ratio = -0.44

Minimum Annual Increase = -Infinity%

Minimum Annual PE Ratio = -12.92

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.44-3.18%
2022-0.45-90.47%
2021-4.75-8.60%
2020-5.1966.46%
2019-3.12-11.30%
2018-3.5217.03%
2017-3.0053.08%
2016-1.96-80.14%
2015-9.89-23.46%
2014-12.92-Infinity%

Aeglea BioTherapeutics, Inc. (AGLE) Average PE Ratio

How has AGLE PE Ratio performed in the past?

The current PE Ratio of Aeglea BioTherapeutics, Inc. (AGLE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.88

5-year avg

-2.79

10-year avg

-4.52

Aeglea BioTherapeutics, Inc. (AGLE) PE Ratio vs. Peers

How is AGLE’s PE Ratio compared to its peers?

Aeglea BioTherapeutics, Inc.’s PE Ratio is greater than Edgewise Therapeutics, Inc. (-22.36), greater than Ikena Oncology, Inc. (-1.24), greater than Design Therapeutics, Inc. (-7.53), greater than Xilio Therapeutics, Inc. (-1.16), less than Eliem Therapeutics, Inc. (0), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Landos Biopharma, Inc. (-5.74), greater than Apexigen, Inc. (-0.24), less than Navidea Biopharmaceuticals, Inc. (0.00), greater than Angion Biomedica Corp. (-0.46), greater than SAB Biotherapeutics, Inc. (-0.83), greater than Senti Biosciences, Inc. (-0.27), less than Cingulate Inc. (-0.00), greater than Bellicum Pharmaceuticals, Inc. (-0.28), greater than Hillstream BioPharma, Inc. (-0.99), greater than Neoleukin Therapeutics, Inc. (-5.86), less than CytomX Therapeutics, Inc. (6.58), greater than Assembly Biosciences, Inc. (-2.29), greater than Instil Bio, Inc. (-1.89), greater than Nuvation Bio Inc. (-1.45), greater than Applied Molecular Transport Inc. (-0.43), greater than Catalyst Biosciences, Inc. (-28.21), greater than Aileron Therapeutics, Inc. (-1.61), greater than Bio-Path Holdings, Inc. (-0.30), greater than Benitec Biopharma Inc. (-5.91),

Build a custom stock screener for Aeglea BioTherapeutics, Inc. (AGLE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aeglea BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aeglea BioTherapeutics, Inc. (AGLE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aeglea BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Aeglea BioTherapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Aeglea BioTherapeutics, Inc. (AGLE)?

What is the highest PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?

What is the 3-year average PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?

What is the 5-year average PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE)?

How does the current PE Ratio for Aeglea BioTherapeutics, Inc. (AGLE) compare to its historical average?